Exogenous nitric oxide inhibits IRS-1 expression in rat hepatocytes and skeletal myocytes

Journal of Biomedical Science

Volumn 13, Issue 4, 2006, Pages 561-568

  Badal, Simone ^a   Brown, Paul D ^a   Ragoobirsingh, Dalip ^a  

^a UNIVERSITY OF THE WEST INDIES   (Jamaica)

Author keywords

2 (4 carboxyphenyl) 4,4,5,5 tetramethylimidazoline 1 oxyl 3 oxide (carboxy PTIO); Insulin receptor substrate 1; Nitric oxide; S nitroso N acetylpenicillamine (SNAP); S nitrosoglutathione (GSNO); Signal transduction

Indexed keywords

2 (4 CARBOXYPHENYL) 4,4,5,5 TETRAMETHYLIMIDAZOLINE 1 OXYL 3 OXIDE; INSULIN; INSULIN RECEPTOR SUBSTRATE 1; N ACETYL S NITROSOPENICILLAMINE; NITRIC OXIDE; S NITROSOGLUTATHIONE; SCAVENGER RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETOGENESIS; DRUG POTENCY; FEMALE; LIVER CELL; MALE; MUSCLE CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; SKELETAL MUSCLE;

ANIMALS; BENZOATES; GENE EXPRESSION REGULATION; GLUTATHIONE; HEPATOCYTES; IMIDAZOLES; IMMUNOBLOTTING; MUSCLE FIBERS; NITRIC OXIDE; NITRO COMPOUNDS; PENICILLAMINE; PHOSPHOPROTEINS; RATS; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 33745622820     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1007/s11373-006-9073-y     Document Type: Article

References (32)

1. Cavaghan M.K., Ehrmann D.A. and Polonsky K.S., Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J. Clin. Invest. 106: 329-333, 2000.
2. Khan S.E., The importance of β-cell failure in the development and progression of type I.I. diabetes. J. Clin. Endocrinol. Metab 86: 4047-4058, 2001.
3. DeFronzo R.A., The triumvirate: β-cell, muscle, liver: a collision responsible for N.I.DDM. Lilly Lecture. Diabetes 37: 667-687, 1987.
4. Morris F., White C. and Ronald K., Insulin signaling system. J. Biol. Chem. 269: 1-4, 1994.
5. Culotta E. and Koshlanf D.E. Jr., No news is good news. Science 258: 1862-1865, 1992.
6. DeFronzo R.A., Bonadonna R.C. and Ferrannini E., Pathogenesis of N.I.DDM: a balanced overview. Diabetes Care 15: 318-368, 1992.
7. Ulrich A., Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 313: 756-761, 1985.
8. Lane P. and Gross S.S., Cell signaling by nitric oxide. Semin. Nephrol. 19: 215-229, 1999.
9. Gross S.S. and Wolin M.S., Nitric oxide: pathophysiological mechanisms. Annu. Rev. Physiol. 57: 737-769, 1995.
10. Stamler J.S., Janki O. and Osborne J.A., Nitric oxide circulates in mammalian plasma primarily as an S-nitrosoproduct of serum albumin. Proc. Nat. Acad. Sci. USA 89: 7624-7677, 1992.
11. McGrowder D., Ragoobirsingh D. and Dasgupta T., Decreased insulin binding to mononuclear leucocytes and erythrocytes from dogs after S-nitroso-N- acetylpenicillamine administration. BMC Biochem. DOI:10.1186/1471-2091-3-1.
12. Ragoobirsingh D., McGrowder D., Barrett K. and Brown P.D., Direct effect of nitric oxide on basal and insulin-stimulated glucose transport in rat skeletal muscle (Abstract). West Indian Med. J. 52((Suppl. 6) 15, 2003.
13. Barrett K., McGrowder D., Brown P.D. and Ragoobirsingh D., Nitric oxide inhibits insulin-stimulated glucose transport in adipocytes (Abstract). West Indian Med. J. 53(Suppl. 2) 52-53, 2004.
14. Freshney R., Culture of animal cells: a manual of basic techniques. Alan R. Liss, Inc, New York, 1987, 117.
15. Bradford M.M., A rapid and sensitive method for the quantitation of microgram quantities of protein, utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254, 1976.
16. Rasband W.S. and Image J., U.S. National Institutes of Health, Bethesda, Maryland, USA, http://www.rsb.info.nih.gov/ij/, 1997-2005;2005.
17. Broillet M.C., S-nitrosylation of proteins. Cell Mol. Life Sci. 55: 1036-1042, 1999.
18. Foster M.W., McMahon T.J. and Stamler J.S., S-nitrosylation in health and disease. Trends Mol. Med. 9: 160-168, 2003.
19. Stamler J.S., Lamas S. and Fang F.C., Nitrosylation: the prototypic redox-based signaling mechanism. Cell 106: 675-683, 2001.
20. Carvalho-Filho M.A., Ueno M., Hirabara S.M., Seabra A.B., Carvalheira J.B.C., de Oliveira M.G., Velloso L.A., Curi R. and Saad M.J.A., S-nitrosation of the insulin receptor, insulin receptor substrate 1, and protein kinase B/Akt: a novel mechanism of insulin resistance. Diabetes 54: 959-967, 2005.
21. Sugita H., Sugita M. and Kaneki M., iNOS gene disruption restores depressed I.R.S-1 expression in skeletal muscle and ameliorates insulin resistance in (ob/ob) mice (Abstract). Diabetes 52((Suppl. 1) A299, 2003.
22. Elchebly M., Payette P., Michaliszyn E., Cromlish W., Collins S., Loy A.L., Normandin D., Cheng A., Himms-Hagen J., Chan C.C., Ramachandran C., Gresser M.J., Tremblay M.L. and Kennedy B.P., Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283: 1544-1548, 1999.
23. Hotamisligil G.S., Peraldi P., Budavari A., Ellis R., White M.F. and Spiegelman B.M., IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in T.N.F-alpha-and obesity-induced insulin resistance. Science 271: 665-668, 1996.
24. Gao Z., Hwang D., Bataille F., Lefevre M., York D., Quon M.J. and Ye J., Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex. J. Biol. Chem. 277: 48115-48121, 2002.
25. Liu Y.F., Herschkovitz A., Boura-Halfon S., Ronen D., Paz K., Leroith D. and Zick Y., Serine phosphorylation proximal to its phosphotyrosine binding domain inhibits insulin receptor substrate 1 function and promotes insulin resistance. Mol. Cell Biol. 24: 9668-9681, 2004.
26. Pederson T.M., Kramer D.L. and Rondinone C.M., Serine/threonine phosphorylation of I.R.S-1 triggers its degradation: possible regulation by tyrosine phosphorylation. Diabetes 50: 24-31, 2001.
27. Ricort J.M., Tanti J.F., Van Obberghen E. and Le Marchand-Brustel Y., Different effects of insulin and platelet-derived growth factor on phosphatidylinositol 3-kinase at the subcellular level in 3T3-L1 adipocytes. A possible explanation for their specific effects on glucose transport. Eur. J. Biochem. 239: 17-22, 1996.
28. Zhande R., Mitchell J.J., Wu J. and Sun X.J., Molecular mechanism of insulin-induced degradation of insulin receptor substrate 1. Mol. Cell Biol. 22: 1016-1026, 2002.
29. Pfeiffer S., Leopold E., Hemmens B., Schmidt K., Werner E.R. and Mayer B., Interference of carboxy-PTIO with nitric oxide- and peroxynitrite-mediated reactions. Free Radic. Biol. Med. 22(5) 787-94, 1997.
30. Ishii M., Shimizu S., Momose K. and Yamamoto T., SIN-1-induced cytotoxicity in cultured endothelial cells involves reactive oxygen species and nitric oxide: Protective effect of sepiapterin. J. Cardiovas Pharmacol. 33: 295-300, 1999.
31. Durán-Reyes G., Pascoe-Lira D., Vilar-Rojas C., Medina-Navarro R., Díaz-Flores M., Ortega-Camarillo C., García-Macedo R., Cruz M. and Rodríguez J.K., Diabetogenic effect of S.T.Z diminishes with the loss of nitric oxide: Role of ultraviolet light and carboxy-PTIO. Pharmacology 71: 17-24, 2004.
32. Takahashi K., Numata N., Kinoshita N., Utoguchi N., Mayumi T. and Mizuno N., Characterization of the influence of nitric oxide donors on intestinal absorption of macromolecules. Int. J. Pharm. 286: 89-97, 2004.